Table 3.

Prognostic factors of PFS or OS

FactorsPFSOS
Sex (male/female)0.9540.297
Age (≥65/<65)0.7280.544
Primary tumor site (I/G, I/E, G/E)a0.679, 0.207, 0.3640.235, 0.207, 0.364
LY6K CTL spots (≥25/<25)0.0020.002
TTK CTL spots (≥25/<25)0.0170.005
DEPDC1 CTL spots (≥25/<25)0.0020.002
LY6K multimer + CTLs (≥10%/<10%)0.1130.840
CXCR3+CCR4 (≥8%/<8%)0.0170.005
Skin reaction of vaccine site (≥G2/<G2)0.0030.003
Vaccine dose (0.5 mg/1 mg, 0.5 mg/2 mg, 1 mg/2 mg)0.988, 0.988, 0.6940.343, 0.343, 0.832
Lymphocyte (%; ≥30%/<30%)0.5450.423
Lymphocyte (number; ≥1,500/<1,500)0.1550.155
  • aPrimary tumor site: E, extrahepatic bile duct; G, gallbladder; I, intrahepatic bile duct.